SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after its ANKTIVA bladder cancer treatment received European Commission authorization, significantly expanding its global market. This news, combined with high short interest, is igniting community speculation about a massive short squeeze and increasing anticipation for further global approvals.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after its recent earnings showed a significant EPS beat attributed largely to non-cash tax benefits, overshadowing an Adjusted EBITDA miss and fueling community concerns about "accounting magic" and opaque related-party dealings.

B2Gold Corp. is an exploration company, which engages in the acquisition and development of mineral properties. It operates through the following segments: Fekola Mine, Fekola Regional, Masbate Mine, Otjikoto Mine, Goose Project, Other Mineral Properties, and Corporate and Other. The Fekola Regional segment consists of Bantako North, Menankoto, Dandoko, and Bakolobi properties. The Other Mineral Properties segment focuses on the company interests in mineral properties which are at various stages of exploration and evaluation. The Corporate and Other segment includes the corporate operations. The company was founded by Mark Anthony Corra, Thomas A. Garagan, Clive Thomas Johnson, and Roger Thomas Richer on November 30, 2006 and is headquartered in Vancouver, Canada.

B2gold Corp

B2Gold is trending following its recent earnings and 2026 guidance, sparking a polarized community debate where some investors see deep undervaluation amidst high gold prices, while others criticize management's execution and project outlook.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending after its recent earnings presented mixed results, including revenue and net income misses, but strong order growth and a better-than-expected Marketplace GOV outlook sparked a dramatic price reversal. The community is actively debating whether the rally is a short squeeze or reflects underlying business strength.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending after reporting a strong quarterly earnings beat and completing the sale of its chemical business to Berkshire Hathaway, which substantially strengthened its balance sheet. The community is actively discussing these fundamental improvements and the ongoing geopolitical tensions impacting global oil supply as potential tailwinds for the energy sector.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as market participants debate how a proposed credit card interest rate cap could significantly benefit its merchant-funded, 0% interest buy-now-pay-later model, contrasting it sharply with traditional lenders. Despite its post-IPO struggles and current low valuation, many investors are highlighting Klarna's expanding partnerships and low default rates as reasons for a potential rebound.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is trending due to a significant partnership with the U.S. government and Brookfield to accelerate nuclear reactor deployment, a development seen by the community as vital for powering future AI growth and bolstering energy security. This initiative highlights Cameco's central role in the burgeoning nuclear energy renaissance and is driving widespread bullish sentiment despite some valuation concerns.

ARK Investment Management LLC - ARK Innovation ETF

ARK Innovation ETF

ARKK is trending due to polarized community sentiment surrounding Cathie Wood's active portfolio adjustments, notably her continued buying of crypto-linked stocks like Coinbase and BitMine Immersion, alongside reducing exposure to names such as Tesla. Investors are debating if these actions signify high conviction in disruptive innovation or point to ongoing underperformance and capital destruction within the speculative growth sector.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly awaits the February 21 PDUFA decision for Bysanti, which many view as a significant catalyst alongside the blockbuster potential of Tradipitant for GLP-1 induced nausea, fueling ongoing speculation of a major valuation re-rating or buyout despite recent dips.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending higher after strong earnings and an optimistic 2026 outlook, underscoring its dominance in the GLP-1 market against rivals like Novo Nordisk, while community discussions also highlight its strategic investments in manufacturing and pipeline diversification amid regulatory actions against compounded weight-loss drugs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.4% - Time to Sell?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.4% - What's Next...

EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?

EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sees Unusually-High Trading Volume - Time to Buy?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sees Large Volume Increase - What's Next...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, Marketbeat.com reports. One research...

EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program

EyePoint Pharmaceuticals (NASDAQ:EYPT) used a presentation at the Guggenheim Emerging Biotech Emerging Outlook Biotech Summit 2026 to outline upcoming clinical catalysts for its lead retinal program...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 7.8% Higher - Here's Why

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.8% - What's Next...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% - Here's What Happened

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% - Should You Sell...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Time to Buy?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - What's Next...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6% - Here's Why

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.6% - What's Next...

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EYPT News

EYPTEyePoint Pharmaceuticals Inc